The news highlights:
A new report by Global Market Insights, Inc. (DE, USA) has estimated that the global market for cancer gene therapy will be worth over US$2.5 billion by 2025. With a backdrop of increased investment in developing countries, the report suggests the emergence of new technologies such as efficient viral vectors will allow the industry to boom.
“The pipeline for cancer gene therapy is quite strong and recently several industry players have been focused on developing several effective cancer gene therapies and its vectors. Marketing of cancer gene therapy requires pre-marketing authorization and it is a rigorous process that is scrutinized stringently. Therefore, few cancer gene therapies are available in the market and it is still in developing phase. However, vectors, the pre-requisites of gene therapy are required for gene transfer are increasingly being adopted for research and treatment purposes,” reported Global Market Insights.
In a step towards their fully integrated gene therapy delivery system, this week, Lonza (Basel, Switzerland) have announced their partnership with Cryoport (CA, USA) for the global delivery of patient tissues. Utilizing Cryport’s logistical management platform, this moves Lonza closer to delivering seamless solutions for all manufacturing and logistical needs in relation to personalized therapeutics and gene therapy.
"The Lonza-Cryoport collaboration is an enabling part of a wider goal for Lonza to create a network of strategic partnerships and capabilities that enable seamless vein-to-vein delivery of cell and gene therapies for its customers and their patients. There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency,” stated Alberto Santagostino (Lonza Pharma & Biotech).
This week, research published in Science by a team from The Rockefeller University (NY, USA), proposed a new function of the lymphatic system in the context of hair regeneration. The new research has uncovered a role for the lymphatic system in communication between stem cell niches through a complicated network integrated into the niche, answering a long-held question about the ability of stem cells to coordinate.
“The involvement of the lymphatic system in this process is a new concept and might potentially provide new therapeutic targets for lymph-related conditions such as wound-healing defects and hair loss,” concludes Elaine Fuchs (The Rockefeller University), lead author of the paper.
For more weekly cell therapy news, read previous editions of the cell therapy weekly.
Have any additional questions about this story? Ask us in the comments, below.
Find out more in these top picks from the Editor:
- Computational fluid dynamics could enable effective and efficient scale up of gene therapy
- New CRISPR cell therapy overcomes first hurdle in trial
- Industry updates with Dusko Ilic: July 2019